Although there is little biological reason to be concerned that CGRP antagonists may predispose patients to greater risk of contracting COVID-19, there is limited clinical evidence on the safety of prescribing CGRP mAbs for patients with migraine at risk of COVID-19. Here, CALCA is linked to migraine disorder.